Isoliquiritigenin Nanosuspension Enhances Cytostatic Effects in A549 Lung Cancer Cells

Abstract

Isoliquiritigenin, a flavonoid extracted from licorice root, has been shown to be active against most cancer cells; however, its antitumor activity is limited by its poor water solubility. The aim of this study was to develop a stable isoliquiritigenin nanosuspension for enhanced solubility and to evaluate its in vitro cytostatic activity in A549 cells. The nanosuspension of isoliquiritigenin was prepared through wet media milling with HPC SSL (hydroxypropyl cellulose-SSL) and PVP K30 (polyinylpyrrolidone-K30) as stabilizers, and the samples were then characterized according to particle size, zeta-potential, SEM (scanning electron microscopy), TEM (transmission electron microscopy), DSC (differential scanning calorimetry), XRPD (X-ray powder diffraction), FTIR (Fourier transform infrared spectroscopy), XPS (X-ray photoelectron spectroscopy), and in vitro release. The isoliquiritigenin nanosuspension prepared with HPC SSL and PVP K30 had particle sizes of 238.1 ± 4.9 nm and 354.1 ± 9.1 nm, respectively. Both nanosuspensions showed a surface charge of approximately − 20 mV and a lamelliform or ellipse shape. The dissolution of isoliquiritigenin from the 2 nanosuspensions was markedly higher than that of free isoliquiritigenin. In vitro studies on A549 cells indicated that the cytotoxicity and cellular uptake significantly improved after treatment with both nanosuspensions in comparison to the isoliquiritigenin solution. Furthermore, cell apoptosis analysis showed a 7.5 – 10-fold increase in the apoptosis rate induced by both nanosuspensions compared with pure drug. However, the cytotoxicity of pure drug and nanosuspension on normal cells (HELF) was lower, which indicated both isoliquiritigenin nanosuspensions have low toxicity to normal cells. Therefore, the isoliquiritigenin nanosuspension prepared with HPC SSL and PVP K30 as stabilizers may be a promising approach to improve the solubility and cytostatic activity of isoliquiritigenin.

Key words

isoliquiritigenin - nanosuspension - dissolution - lung cancer cells - cytotoxicity

• References

• 1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69: 7-34
• 2 Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL, Siegel RL. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin 2019; 69: 363-385
• 3 Kibria G, Hatakeyama H, Harashima H. Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system. Arch Pharm Res 2014; 37: 4-15
• 4 Wu CP, Hsieh CH, Wu YS. The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy. Mol Pharm 2011; 8: 1996-2011
• 5 Gao S, Li X, Ding X, Qi W, Yang QF. Cepharanthine induces autophagy, apoptosis and cell cycle arrest in breast cancer cells. Cell Physiol Biochem 2017; 41: 1633-1648
• 6 Ren M, Xu WJ, Xu T. Salidroside represses proliferation, migration and invasion of human lung cancer cells through AKT and MEK/ERK signal pathway. Artif Cells Nanomed Biotechnol 2019; 47: 1014-1021
• 7 Tan KT, Lin MX, Lin SC, Tung YT, Lin SH, Lin CC. Sinensetin induces apoptosis and autophagy in the treatment of human T-cell lymphoma. Anticancer Drugs 2019; 30: 485-494
• 8 Boyapelly K, Bonin MA, Traboulsi H, Cloutier A, Phaneuf SC, Fortin D, Cantin AM, Richter MV, Marsault E. Synthesis and characterization of a phosphate prodrug of isoliquiritigenin. J Nat Prod 2017; 80: 879-886
• 9 Peng F, Du QH, Peng C, Wang N, Tang HL, Xie XM, Shen JG, Chen JP. A review: the pharmacology of isoliquiritigenin. Phytother Res 2015; 29: 969-977
• 10 Wu CH, Chen HY, Wang CW, Shieh TM, Huang TC, Lin LC, Wang KL, Hsia SM. Isoliquiritigenin induces apoptosis and autophagy and inhibits endometrial cancer growth in mice. Oncotarget 2016; 7: 73432-73447
• 11 Tian T, Sun JP, Wang JX, Liu YC, Liu HT. Isoliquiritigenin inhibits cell proliferation and migration through the PI3K/AKT signaling pathway in A549 lung cancer cells. Oncol Lett 2018; 16: 6133-6139
• 12 Jin H, Seo GS, Lee SH. Isoliquiritigenin-mediated p62/SQSTM1 induction regulates apoptotic potential through attenuation of caspase-8 activation in colorectal cancer cells. Eur J Pharmacol 2018; 841: 90-97
• 13 Wang TT, Chen ZZ, Xie P, Zhang WJ, Du MY, Liu YT, Zhu HY, Guo YS. Isoliquiritigenin suppresses the proliferation and induced apoptosis via miR-32/LATS2/Wnt in nasopharyngeal carcinoma. Eur J Pharmacol 2019; 856: 172352
• 14 Li N, Yang L, Deng XN, Sun YN. Effects of isoliquiritigenin on ovarian cancer cells. Onco Targets Ther 2018; 11: 1633-1642
• 15 Xie YJ, Wang QL, Adu-Frimpong M, Liu J, Zhang KY, Xu XM, Yu JN. Preparation and evaluation of isoliquiritigenin-loaded F127/P123 polymeric micelles. Drug Dev Ind Pharm 2019; 45: 1224-1232
• 16 Zhang KY, Wang QL, Yang QX, Wei QY, Man N, Adu-Frimpong M, Toreniyazov E, Ji H, Yu JG, Xu XM. Enhancement of oral bioavailability and anti-hyperuricemic activity of isoliquiritigenin via self-microemulsifying drug delivery system. AAPS PharmSciTech 2019; 20: 218
• 17 Zhang XY, Qiao H, Ni JM, Shi YB, Qiang Y. Preparation of isoliquiritigenin-loaded nanostructured lipid carrier and the in vivo evaluation in tumor-bearing mice. Eur J Pharm Sci 2013; 49: 411-422
• 18 Li B, Liu BG, Li JQ, Xiao HZ, Wang JY, Liang GZ. Experimental and theoretical investigations on the supermolecular structure of isoliquiritigenin and 6-O-α-D-maltosyl-β-cyclodextrin inclusion complex. Int J Mol Sci 2015; 16: 17999-18017
• 19 Wang YT, Wang CY, Zhao J, Ding YF, Li L. A cost-effective method to prepare curcumin nanosuspensions with enhanced oral bioavailability. J Colloid Interface Sci 2017; 485: 91-98
• 20 Singh MK, Pooja D, Ravuri HG, Gunukula A, Kulhari H, Sistla R. Fabrication of surfactant-stabilized nanosuspension of naringenin to surpass its poor physiochemical properties and low oral bioavailability. Phytomedicine 2018; 40: 48-54
• 21 Medarević D, Djuriš J, Ibrić S, Mitrić M, Kachrimanis K. Optimization of formulation and process parameters for the production of carvedilol nanosuspension by wet media milling. Int J Pharm 2018; 540: 150-161
• 22 Bilgili E, Li M, Afolabi A. Is the combination of cellulosic polymers and anionic surfactants a good strategy for ensuring physical stability of BCS Class II drug nanosuspensions?. Pharm Dev Technol 2016; 21: 499-510
• 23 Kim HI, Park SY, Park SJ, Lee J, Cho KH, Jee JP, Kim HC, Maeng HJ, Jang DJ. Development and evaluation of a reconstitutable dry suspension to improve the dissolution and oral absorption of poorly water-soluble celecoxib. Pharmaceutics 2018; 10: 140
• 24 Patel PJ, Gajera BY, Dave RH. A quality-by-design study to develop nifedipine nanosuspension: examining the relative impact of formulation variables, wet media milling process parameters and excipient variability on drug product quality attributes. Drug Dev Ind Pharm 2018; 44: 1942-1952
• 25 Chingunpitak J, Puttipipatkhachorn S, Chavalitshewinkoon PP, Tozuka Y, Moribe K, Yamamoto K. Formation, physical stability and in vitro antimalarial activity of dihydroartemisinin nanosuspensions obtained by co-grinding method. Drug Dev Ind Pharm 2008; 34: 314-322
• 26 Thakkar S, Sharma D, Misra M. Comparative evaluation of electrospraying and lyophilization techniques on solid state properties of erlotinib nanocrystals: assessment of in-vitro cytotoxicity. Eur J Pharm Sci 2018; 111: 257-269
• 27 Gao Y, Li ZG, Sun M, Guo CY, Yu AH, Xi YW, Cui J, Lou HX, Zhai GX. Preparation and characterization of intravenously injectable curcumin nanosuspension. Drug Deliv 2011; 18: 131-142
• 28 Gol D, Thakkar S, Misra M. Nanocrystal-based drug delivery system of risperidone: lyophilization and characterization. Drug Dev Ind Pharm 2018; 44: 1458-1466
• 29 Homayouni A, Sohrabi M, Amini M, Varshosaz J, Nokhodchi A. Effect of high pressure homogenization on physicochemical properties of curcumin nanoparticles prepared by antisolvent crystallization using HPMC or PVP. Mater Sci Eng C Mater Biol Appl 2019; 98: 185-196
• 30 Yakushiji K, Ogino M, Suzuki H, Seto Y, Sato H, Onoue S. Physicochemical and biopharmaceutical characterization of celecoxib nanoparticle: avoidance of delayed oral absorption caused by impaired gastric motility. Int J Pharm 2018; 552: 453-459
• 31 Qin C, Xin XF, Pei X, Yin LF, He W. Amorphous nanosuspensions aggregated from paclitaxel-hemoglobulin complexes with enhanced cytotoxicity. Pharmaceutics 2018; 10: 92
• 32 Feng FF, Zhang DR, Tian KL, Lou HY, Qi XL, Wang YC, Duan CX, Jia LJ, Wang FH, Liu Y, Zhang Q. Growth inhibition and induction of apoptosis in MCF-7 breast cancer cells by oridonin nanosuspension. Drug Deliv 2011; 18: 265-271
• 33 Lou HY, Gao L, Wei XB, Zhang Z, Zheng DD, Zhang DR, Zhang XM, Li Y, Zhang Q. Oridonin nanosuspension enhances anti-tumor efficacy in SMMC-7721 cells and H22 tumor bearing mice. Colloids Surf B Biointerfaces 2011; 87: 319-325
• 34 Hong JY, Li YH, Xiao Y, Li YJ, Guo YF, Kuang HX, Wang XT. Annonaceous acetogenins (ACGs) nanosuspensions based on a self-assembly stabilizer and the significantly improved anti-tumor efficacy. Colloids Surf B Biointerfaces 2016; 145: 319-327
• 35 Talekar M, Ganta S, Amiji M, Jamieson S, Kendall J, Denny WA, Garg S. Development of PIK-75 nanosuspension formulation with enhanced delivery efficiency and cytotoxicity for targeted anti-cancer therapy. Int J Pharm 2013; 450: 278-289
• 36 Bi C, Miao XQ, Chow SF, Wu WJ, Yan R, Liao YH, Chow AH, Zheng Y. Particle size effect of curcumin nanosuspensions on cytotoxicity, cellular internalization, in vivo pharmacokinetics and biodistribution. Nanomedicine 2017; 13: 943-953
• 37 Gratton SEA, Ropp PA, Pohlhaus PD, Luft JC, Madden VJ, Napier ME, DeSimone JM. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci U S A 2008; 105: 11613-11618